Biosimilar infliximab gains FDA Advisory Committee endorsement

A biosimilar agent to Remicade, the brand-name and reference form of infliximab, stayed on track to become the second biosimilar drug to enter the U.S. market...

Source: Rheumatology News - February 10, 2016 Category: Rheumatology Source Type: research